{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-026107","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.563596+00:00","generated_at":"2026-06-01T22:56:08.819423+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PDS Biotech Q1 net loss $10.6M; VERSATILE-002 shows median OS of 30 months in HNSCC","bullets":["VERSATILE-002 Phase 2: median overall survival 30 months (vs 7-18 months for ICIs); BOR 34% (CPS≥1), 48% (CPS≥20).","Updated registrational trial strategy: triple combination Versamune HPV + PDS01ADC + pembrolizumab in first-line HNSCC.","Appointed Stephan Toutain as COO; brings commercial experience.","Two patents granted by Israel and Australia extending Versamune platform protection through 2036-2038.","Q1 net loss $10.6M ($0.30/share); cash $66.6M; R&D expenses $6.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-026107","json":"https://secwatch.observer/filing/0001140361-24-026107.json","markdown":"https://secwatch.observer/filing/0001140361-24-026107.md","text":"https://secwatch.observer/filing/0001140361-24-026107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124026107/0001140361-24-026107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124026107/ef20029143_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:56:08.819423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"795bb6390212d0f1a88f22b75ca227b046475b73","claim":"PDS Biotechnology Corp reported the three months ended March 31, 2024 results: net income approximately $10.6 million, EPS $0.30 per basic share and diluted share.","evidence_excerpt":"Reported net loss was approximately $10.6 million, or $0.30 per basic share and diluted share, for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124026107/0001140361-24-026107-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"approximately $10.6 million"},{"label":"EPS","value":"$0.30 per basic share and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}